This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
23andMe in February said it s going public in a deal that values the company at $3.5 billion.
Despite 23andMe s success, the consumer genomics market has largely bottomed out, an analyst said.
Others hoping to cash in on genetic health assessments have pivoted or shuttered efforts altogether.
As consumer genetics giant 23andMe prepares to go public, the personal genetics market isn t what it once was. We ve kind of hit the bottom and we re stable right now, Evercore analyst Vijay Kumar told Insider.
But that hasn t stopped competitors from building out niches in other areas.
Project Well, a startup taking a nutritional approach to chronic disease, raised $2 million.
The startup plans to target the booming Medicare Advantage market.
It works with food vendors and dietitians to get patients to eat healthier and manage conditions.
Throughout her career, Lauren Driscoll has made caring for older adults a priority.
After college, she went to work at a high school in Japan, a country where older people are given higher social status. Her grandmother also served as inspiration for her work, which began when Driscoll pursued a master s in public health at Columbia University in the 1990s.
Driscoll is a veteran of the 1993 Clinton Health Care Task Force, where she helped craft healthcare reform. During her time at Oxford Health Plans (now owned by UnitedHealth Group) and Leavitt Partners, Driscoll has kept an eye on how Medicare, the health insurance for adults 65 and older, has transformed over the past three decades.
Thomson Reuters
But the drug missed most of the secondary trial goals, including one watched by experts.
An Eli Lilly executive told Insider the data was mixed, but very exciting.
The latest test of Eli Lilly s Alzheimer s disease drug ended with a mixed bag of results that disappointed investors.
Lilly gave an in-depth look at the performance of its drug, called donanemab, on Saturday at the International Conference on Alzheimer s and Parkinson s Diseases. The drug met the trial s primary goals, reducing a harmful substance that builds up in the brains of patients with Alzheimer s disease. It also slowed down the rate of cognitive decline by 32%, according to data published Saturday in a medical journal. But it missed the mark on several secondary tests.